Fluo Labs

Fluo Labs is pioneering a potential breakthrough light-based technology designed to help allergy sufferers reduce their allergy symptoms without having to use medication. Over 50 Million Americans and 1 Billion more people worldwide suffer from allergies. And thanks to climate change, allergy seasons are only getting longer, more intense and affecting more and more people every year. And while the global allergy treatment market is growing and set to reach $40 billion by 2025, we believe it is under serviced, leaving 66% of allergy sufferers to report dissatisfaction with their current allergy medications.A team that’s changing allergy relief:  With multiple patents granted and filed and a successful proof-of-concept study, the team is now set to complete the clinical evaluations and final studies that are needed to obtain an FDA de Novo grant which we hope to obtain by the end of 2021.

A new category in allergy care: Fluo Labs is pioneering a potential breakthrough light-based technology designed to help allergy sufferers reduce their allergy symptoms without having to use medication.
A huge and growing market: Over 50 Million Americans and 1 Billion more people worldwide suffer from allergies. And thanks to climate change, allergy seasons are only getting longer, more intense and affecting more and more people every year. And while the global allergy treatment market is growing and set to reach $40 billion by 2025, we believe it is under serviced, leaving 66% of allergy sufferers to report dissatisfaction with their current allergy medications.
A team that’s changing allergy relief: With multiple patents granted and filed and a successful proof-of-concept study, the team is now set to complete the clinical evaluations and final studies that are needed to obtain an FDA de Novo grant which we hope to obtain by the end of 2021.

Richard Clement, M.D., F.A.C.S.,
Chairman of the Board of Directors and President of Fluo Labs, Inc.
President and Angel InvestorSerial investor and entrepreneur (CLRS Technology and Arrestage International). Dr. Clement is plastic surgeon and leads a successful practice in Scottsdale AZ.

Paul Rubin, MD, Chief Medical Officer
Extensive experience in multiple pharma/biotech therapeutic areas. Involved with discovery, preclinical and clinical development, regulatory and marketing in global and emerging drug companies. Experience with antihistamines and nasal steroids. GSK, Abbott, Xoma, Sepracor.

Jan Enemaerke, Chief Technology Officer
Expert in lasers and medical optical engineering. Senior executive positions (US & Europe). BSc in mechanical engineering, MBA.

Anne-Marie Kovacs, Chief Strategy Officer
Creative strategist to emerging companies. Marketing, strategic foresight, project management, operations, business development, brand management, creative development.

Lawrence Johnson, CEO
Seasoned entrepreneur, health informatics., data analytics, medical device start-ups. Board of CLRS Technology. Successful exits: yellowpages.com (digital), RightPond (fintech), CLRS (devices)